[{"id":"4f64537c-30ea-40b5-a6ea-986f53ce0892","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170568","created_at":"2021-12-28T19:16:09.401Z","updated_at":"2024-07-02T16:36:01.493Z","phase":"Phase 1","brief_title":"PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies","source_id_and_acronym":"NCT05170568","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD8 • IL6 • CD4 • CD7","pipe":"","alterations":" ","tags":["CD8 • IL6 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PA3-17"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-11-01"},{"id":"630b60fa-991b-4055-8389-abe1985f738c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05059912","created_at":"2021-09-28T11:53:03.981Z","updated_at":"2024-07-02T16:36:23.830Z","phase":"Phase 2","brief_title":"CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma","source_id_and_acronym":"NCT05059912","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" CD8 • CD4 • CD7","pipe":"","alterations":" ","tags":["CD8 • CD4 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PA3-17"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/05/2021","start_date":" 08/05/2021","primary_txt":" Primary completion: 08/03/2023","primary_completion_date":" 08/03/2023","study_txt":" Completion: 08/03/2024","study_completion_date":" 08/03/2024","last_update_posted":"2021-09-28"},{"id":"62da845b-0784-4459-bb08-6bdd4e7a1cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762485","created_at":"2021-02-21T13:52:20.902Z","updated_at":"2024-07-02T16:36:29.626Z","phase":"Phase 1/2","brief_title":"Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia","source_id_and_acronym":"NCT04762485","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" CD7","pipe":"","alterations":" ","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PA3-17"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 02/28/2023","primary_completion_date":" 02/28/2023","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2021-06-02"},{"id":"e5c5eae6-8509-4755-adc9-bf7f4b92692e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785833","created_at":"2021-03-08T13:56:36.619Z","updated_at":"2024-07-02T16:36:33.656Z","phase":"","brief_title":"CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia","source_id_and_acronym":"NCT04785833","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PA3-17"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 02/04/2024","study_completion_date":" 02/04/2024","last_update_posted":"2021-03-08"},{"id":"1e3daa68-6b3b-4186-9483-85e89beb933a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04480788","created_at":"2021-01-18T21:30:59.550Z","updated_at":"2024-07-02T16:36:36.509Z","phase":"Phase 1","brief_title":"CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study","source_id_and_acronym":"NCT04480788","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" ALK • CD7","pipe":"","alterations":" ","tags":["ALK • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PA3-17"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 11/24/2020","start_date":" 11/24/2020","primary_txt":" Primary completion: 08/01/2022","primary_completion_date":" 08/01/2022","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2021-01-06"},{"id":"4e098aa7-e645-4938-b6f3-f761ea81d884","acronym":"","url":"https://clinicaltrials.gov/study/NCT04004637","created_at":"2021-01-18T19:40:47.452Z","updated_at":"2024-07-02T16:36:40.642Z","phase":"Phase 1","brief_title":"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT04004637","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • PA3-17"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 08/25/2019","start_date":" 08/25/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-09-28"}]